Media & Resources

Research will continue on COVID-19 vaccine platform.

A study of MTBVAC efficacy in a macaque model of tuberculosis shows that the vaccine candidate protects against aerosol infection with Mycobacterium tuberculosis. Researchers from Europe and the U.S. demonstrate that the MTBVAC vaccine protects better than the current BCG vaccine in a model of tuberculosis in macaques and compare the immunological patterns to those…

Universally accessible HIV Prevention Technologies for African girls and young women through Knowledge applied from behavioral Economics (UPTAKE) presents a unique multidisciplinary collaboration of five leading research institutions in both Africa and Europe.

Aim is production of precursors to broadly neutralizing antibodies.

NEW YORK — OCTOBER 27, 2020 — IAVI announced today the award of US$26.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to support IAVI’s recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate. DTRA’s commitment will enable critical nonclinical development on the vaccine candidate that IAVI is developing…

Partners aim to provide potent neutralizing antibodies for COVID-19 pandemic response.

Organizations across the public and private sectors must join forces to make global access to transformative monoclonal antibody products a priority and a reality. The groups highlight four areas of action: Increase Awareness, Expand Availability, Apply Innovations, and Create New Business Models. The time to act is now to ensure equitable global access to potentially…

Antibody injections could offer HIV protection that would be of special value to women and girls in low-income countries.